Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

Anas Younes, MD
Published Online: Tuesday, May 06, 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

In a session at the 18th Annual International Congress on Hematologic Malignancies®, oncologists discussed how to select patients with lymphoid malignancies for therapy in this era of molecularly-defined subsets of disease. Though tools exist to define mutations in certain diseases, they are not yet guiding therapy in lymphoid malignancies. Younes says he believes this is the future.

There remains a need to learn more about disease subsets and place patients in clinical trials to personalize treatments. This movement from treating all patients with R-CHOP to dissecting disease and offering treatments accordingly will represent a culture change.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

In a session at the 18th Annual International Congress on Hematologic Malignancies®, oncologists discussed how to select patients with lymphoid malignancies for therapy in this era of molecularly-defined subsets of disease. Though tools exist to define mutations in certain diseases, they are not yet guiding therapy in lymphoid malignancies. Younes says he believes this is the future.

There remains a need to learn more about disease subsets and place patients in clinical trials to personalize treatments. This movement from treating all patients with R-CHOP to dissecting disease and offering treatments accordingly will represent a culture change.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Head and Neck CancersJul 31, 20162.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Hematologic MalignanciesJul 31, 20162.5